OCULUS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OCULUS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Mar 10, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Mar 10, 2020 |
| FY2019 | Jun 30, 2019 | $0 | Mar 10, 2020 |
| FY2019 | Mar 31, 2019 | $0 | Mar 10, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 10, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Mar 10, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Mar 10, 2020 |
| FY2019 | Mar 31, 2018 | $0 | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 29, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Mar 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($319.1K) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($327.4K) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($591.2K) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.65M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($1.99M) | Mar 28, 2023 |
| FY2020 | Dec 31, 2020 | ($2.32M) | Mar 15, 2021 |
| FY2020 | Sep 30, 2020 | ($297.0K) | Mar 15, 2021 |
| FY2020 | Jun 30, 2020 | ($84.4K) | Mar 15, 2021 |
| FY2020 | Mar 31, 2020 | ($73.3K) | Mar 15, 2021 |
| FY2020 | Dec 31, 2019 | ($27.9K) | Mar 15, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($2.07M) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | ($1.99M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.77M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($196.6K) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($183.3K) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($230.7K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($453.2K) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($370.0K) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($227.6K) | Mar 31, 2016 |
| FY2014 | Dec 31, 2013 | ($75.1K) | Apr 6, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.0K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $6.9K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $95.9K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.14M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $818.3K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $254.3K | Mar 21, 2022 |
| FY2019 | Dec 31, 2018 | $4.8K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $81.1K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $240.4K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $138.4K | Mar 31, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.2K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $223.5K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $274.5K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $399.5K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $430.7K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $266.6K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $196.6K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $178.5K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $149.6K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $212.9K | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.9K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($146.5K) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($533.0K) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.48M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($1.35M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($779.5K) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($799.8K) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $5.6K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($6.4K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($180.7K) | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.2K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $39.5K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $184.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $717.8K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $2.25M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $496.3K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $383.7K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $6.8K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $28.9K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $68.6K | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($737.8K) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($409.5K) | Mar 20, 2026 |
| FY2025 | Dec 31, 2023 | ($89.8K) | Mar 20, 2026 |
| FY2024 | Dec 31, 2022 | $415.4K | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.12M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $328.2K | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $248.3K | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | ($735.5K) | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($552.3K) | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | ($321.6K) | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.03M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($48.71M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($48.39M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($47.80M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($46.15M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($44.16M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($41.39M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($41.19M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($41.01M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($40.78M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.4K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $11.7K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $156.6K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $687.6K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $2.21M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $490.2K | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $382.5K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $5.6K | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $6.4K | Mar 29, 2019 |
| FY2017 | Dec 31, 2015 | $187.1K | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 91.42M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 91.42M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 91.42M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 91.42M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 91.42M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 86.52M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 67.02M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 45.57M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 45.57M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 45.57M | Mar 29, 2018 |